{"changes":[{"companyHref":"/c/syncromune-com","date":"2026-09-25","documentUrl":null,"domain":"syncromune.com","fact":"latest round","name":"Syncromune","new":{"amountUsd":144828791,"date":"2026-05-11","lead":null,"type":null},"old":{"amountUsd":144828791,"date":"2026-05-11","lead":null,"type":"seed"},"publisher":"sec-edgar","reason":null,"retrievedAt":"2026-05-13","slug":"syncromune-com","status":"attributed","url":"https://whoraisedwhat.com/c/syncromune-com"}],"country":"US","description":"Clinical-stage biopharmaceutical company developing SYNC-T, an in-situ immunotherapy platform for metastatic solid tumors.","domain":"syncromune.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":"syncromune","githubStars":null,"industry":"biotechnology","investors":[],"lat":26.122308,"lng":-80.143379,"location":"Fort Lauderdale, FL","name":"Syncromune","rounds":[{"amountQuarantined":false,"amountUsd":144828791,"currency":"USD","date":"2026-05-11","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-13","status":"attributed","url":null},"status":"attributed","type":null,"url":null}],"slug":"syncromune-com","sources":[{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-13","status":"attributed","url":null},{"fact":"existence","publisher":"syncromune.com","retrievedAt":"2026-05-13","status":"self-reported","url":"https://syncromune.com"},{"fact":"description","publisher":"syncromune.com","retrievedAt":"2026-05-13","status":"self-reported","url":"https://syncromune.com"}],"stage":null,"techStack":["Cloudflare","WordPress 7.0","Yoast SEO 27.6","Yoast SEO Premium 27.5","Underscore.js 1.13.8","Kinsta","Google Analytics","Google Tag Manager","jQuery Migrate 3.4.1","DoubleClick Floodlight","Cloudflare Bot Management","PHP"],"totalRaisedUsd":144828791,"updatedAt":"2026-05-13"}